P7C3-A20
- Product Name
- P7C3-A20
- CAS No.
- 1235481-90-9
- Chemical Name
- P7C3-A20
- Synonyms
- CS-2365;P7C3-A20;P7C3-A20, >=98%;P7C3-A20 ，S0287;N-(3-(3,6-DIBROMO-9H-CARBAZOL-9-YL)-2-FLUOROPROPYL)-3-METHOXYANILINE;9H-Carbazole-9-propanamine, 3,6-dibromo-β-fluoro-N-(3-methoxyphenyl)-;3,6-Dibromo-beta-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine;P7C3-A20 3,6-Dibromo-beta-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine
- CBNumber
- CB22686079
- Molecular Formula
- C22H19Br2FN2O
- Formula Weight
- 506.21
- MOL File
- 1235481-90-9.mol
P7C3-A20 Property
- Boiling point:
- 641.3±55.0 °C(Predicted)
- Density
- 1.57±0.1 g/cm3(Predicted)
- storage temp.
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- solubility
- Soluble in DMSO (40 mg/ml)
- pka
- 3.25±0.50(Predicted)
- form
- solid
- color
- Off-white
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
- InChI
- InChI=1S/C22H19Br2FN2O/c1-28-18-4-2-3-17(11-18)26-12-16(25)13-27-21-7-5-14(23)9-19(21)20-10-15(24)6-8-22(20)27/h2-11,16,26H,12-13H2,1H3
- InChIKey
- XNLTWMQBJFWQOU-UHFFFAOYSA-N
- SMILES
- N1(CC(F)CNC2=CC=CC(OC)=C2)C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P312Call a POISON CENTER or doctor/physician if you feel unwell.
P321Specific treatment (see … on this label).
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P362Take off contaminated clothing and wash before reuse.
P403+P233Store in a well-ventilated place. Keep container tightly closed.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- 24201
- Product name
- P7C3-A20
- Purity
- ≥95%
- Packaging
- 1mg
- Price
- $36
- Updated
- 2024/03/01
- Product number
- 24201
- Product name
- P7C3-A20
- Purity
- ≥95%
- Packaging
- 5mg
- Price
- $145
- Updated
- 2024/03/01
- Product number
- 24201
- Product name
- P7C3-A20
- Purity
- ≥95%
- Packaging
- 10mg
- Price
- $243
- Updated
- 2024/03/01
- Product number
- 24201
- Product name
- P7C3-A20
- Purity
- ≥95%
- Packaging
- 25mg
- Price
- $480
- Updated
- 2024/03/01
- Product number
- W9492
- Product name
- P7C3-A20
- Packaging
- 10mg
- Price
- $154
- Updated
- 2021/12/16
P7C3-A20 Chemical Properties,Usage,Production
Description
P7C3-A20 is a derivative of P7C3 (Item No. 16682) that has proneurogenic and neuroprotective activity. It increases proliferation in the subgranular zone (SGZ) of the adult mouse dentate gyrus in a dose-dependent manner when administered at doses ranging from 0.1 to 10 μM. It also protects U2OS cells from calcium-induced mitochondrial dissolution. In a rat model of traumatic brain injury, P7C3-A20 (10 mg/kg, i.p., twice daily for one week) decreases contusion volume, increases proliferation in the SGZ, and decreases the latency to reach the platform in the Morris water maze to sham surgery control levels. It also prevents or reverses dopaminergic cell death and motor deficits in a 6-OHDA rat model of Parkinson's disease.
Uses
P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment[1][2][3].
Synthesis
1260172-05-1
1235481-90-9
To a vial containing N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-N-(3-methoxyphenyl)-4-nitrobenzenesulfonamide (21.0 mg, 0.030 mmol) were added lithium hydroxide (3.2 mg, 0.134 mmol), N,N-dimethylformamide (0.5 mL, 0.06 M), and mercaptoacetic acid ( 4.2 μL, 0.060 mmol). The reaction mixture was stirred for 1 h at room temperature, then diluted with ethyl acetate and washed sequentially with water, saturated sodium bicarbonate solution, water (3 times) and brine. The organic layer was dried with anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column chromatography (eluent: 30% ethyl acetate/hexane containing 0.2% triethylamine) to give 13.6 mg of the target compound in 88% yield. Another synthetic method: DAST (diethylamino sulfur trifluoride, 0.12 mL, 0.916 mmol) was added dropwise to a solution of 1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol (0.102 g, 0.203 mmol) in anhydrous dichloromethane (6.0 mL), and the reaction was carried out at -78 °C. The reaction mixture was stirred at -78 °C for 1 h, then slowly warmed to 0 °C and kept for 5 h. The reaction was carried out at -78 °C. The reaction was quenched by addition of phosphate buffer (pH=8) and extracted with dichloromethane. The aqueous phase was extracted twice with dichloromethane (10 mL). The combined organic phases were dried with anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by silica gel fast column chromatography (eluent: 20% ethyl acetate/hexane containing 0.2% triethylamine) and the fraction containing the desired fluorinated product was further purified with 40% ethyl acetate/hexane containing 0.1% triethylamine to give 5.7 mg of the target compound. Analytical data for 3,6-dibromo-beta-fluoro-N-(3-methoxyphenyl)-9H-carbazole-9-propanamine: 1H NMR (CDCl3, 500 MHz) δ 8.16 (2H, J = 2.0 Hz), 7.56 (dd, 2H, J = 1.9, 8.7 Hz), 7.31 (d, 2H, J = 8.6 Hz), 7.11 (t, 1H, J = 8.1 Hz), 6.36 (dd, 1H, J = 2.2, 8.1 Hz), 6.23 (dd , 1H, J = 2.0, 8.0 Hz), 6.15 (t, 1H, J = 2.3 Hz), 5.11 (ddd, 1H, J = 4.6, 5.8, 10.4, 47.7 Hz), 4.60 (m, 2H), 4.39 (dm, 2H), 3.95 (t, 1H, J = 6.3 Hz), 3.75 (s, 3H). MS (ESI), m/z: 504.9 (M + 1)+. ([M + 1]+ for C22H19Br2FN2O calculated: 505.0).
in vivo
P7C3-A20 (5-10?mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats) treatment reduces infarct volume; reverses cell loss in the cortex and hippocampus and improves motor function without causing neurotoxicity in HI model rats. P7C3-A20 prevents HI-induced neuronal injury via activation of the PI3K/AKT/GSK3β signaling pathway[1].
| Animal Model: | Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury [1] |
| Dosage: | 5?mg/kg, 10?mg/kg |
| Administration: | Intraperitoneal injection; daily; for 7 days |
| Result: | Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity. |
References
[1] PETER M LOCOCO. Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.[J]. eLife, 2017, 6. DOI:10.7554/elife.29626
[2] MEGHAN O BLAYA. Neuroprotective efficacy of a proneurogenic compound after traumatic brain injury.[J]. Journal of neurotrauma, 2014, 31 5: 476-486. DOI:10.1089/neu.2013.3135
[3] EDWIN VÁZQUEZ-ROSA. P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020: 27667-27675. DOI:10.1073/pnas.2010430117
[4] JUNJIE BAI . The Small Molecule P7C3-A20 Exerts Neuroprotective Effects in a Hypoxic–ischemic Encephalopathy Model via Activation of PI3K/AKT/GSK3β Signaling[J]. Neuroscience, 2020, 441: Pages 197-208. DOI:10.1016/j.neuroscience.2020.05.051
[5] HIDEHIRO OKU. P7C3 Suppresses Neuroinflammation and Protects Retinal Ganglion Cells of Rats from Optic Nerve Crush.[J]. Investigative ophthalmology & visual science, 2017: 4877-4888. DOI:10.1167/iovs.17-22179
P7C3-A20 Preparation Products And Raw materials
Raw materials
Preparation Products
P7C3-A20 Suppliers
- Tel
- 15076683720
- Fax
- 022-23754520
- klq@cw-bio.com
- Country
- China
- ProdList
- 8011
- Advantage
- 55
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 13816107857
- Fax
- qq: 276312098
- sales@fortunechem-sh.com
- Country
- China
- ProdList
- 984
- Advantage
- 58
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- 025-58849295 18951903616;
- Fax
- 025-68650336
- info@adooq.cn
- Country
- China
- ProdList
- 2990
- Advantage
- 60
- Tel
- 13621943973
- Fax
- -
- sales@shjiyipharmatech.com
- Country
- China
- ProdList
- 1166
- Advantage
- 55
- Tel
- 0576-88813233 88205808
- Fax
- 0576-88229589
- sales@taizhoukerui.com
- Country
- China
- ProdList
- 137
- Advantage
- 57
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4757
- Advantage
- 55
- Tel
- 21-619849051-1 18521059765
- synchempharma@aliyun.com
- Country
- China
- ProdList
- 6468
- Advantage
- 55
- Tel
- 021-50908862，442785678，326799392 18721037013
- Fax
- 021-50908862
- siyansales@126.com
- Country
- China
- ProdList
- 9627
- Advantage
- 58
View Lastest Price from P7C3-A20 manufacturers
- Product
- P7C3-A20 1235481-90-9
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- 99% min
- Supply Ability
- 20 tons
- Release date
- 2025-01-02
- Product
- P7C3-A20 1235481-90-9
- Price
- US $1.00/ASSAYS
- Min. Order
- 1ASSAYS
- Purity
- 95%~99%
- Supply Ability
- per week:100kg
- Release date
- 2019-09-05